RHOEN-KLINIKUM AG (RHK.DE) Fundamental Analysis & Valuation

FRA:RHK • DE0007042301

Current stock price

12.3 EUR
-0.1 (-0.81%)
Last:

This RHK.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. RHK.DE Profitability Analysis

1.1 Basic Checks

  • In the past year RHK was profitable.
  • In the past year RHK had a positive cash flow from operations.
  • Each year in the past 5 years RHK has been profitable.
  • Each year in the past 5 years RHK had a positive operating cash flow.
RHK.DE Yearly Net Income VS EBIT VS OCF VS FCFRHK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

1.2 Ratios

  • RHK has a Return On Assets of 1.89%. This is comparable to the rest of the industry: RHK outperforms 48.15% of its industry peers.
  • Looking at the Return On Equity, with a value of 2.61%, RHK is in line with its industry, outperforming 40.74% of the companies in the same industry.
  • RHK has a worse Return On Invested Capital (2.24%) than 70.37% of its industry peers.
  • RHK had an Average Return On Invested Capital over the past 3 years of 2.41%. This is below the industry average of 5.73%.
Industry RankSector Rank
ROA 1.89%
ROE 2.61%
ROIC 2.24%
ROA(3y)2.14%
ROA(5y)1.92%
ROE(3y)3.02%
ROE(5y)2.69%
ROIC(3y)2.41%
ROIC(5y)2.18%
RHK.DE Yearly ROA, ROE, ROICRHK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6

1.3 Margins

  • RHK has a Profit Margin (2.02%) which is in line with its industry peers.
  • RHK's Profit Margin has improved in the last couple of years.
  • RHK's Operating Margin of 2.40% is on the low side compared to the rest of the industry. RHK is outperformed by 74.07% of its industry peers.
  • RHK's Operating Margin has improved in the last couple of years.
  • With a decent Gross Margin value of 66.87%, RHK is doing good in the industry, outperforming 66.67% of the companies in the same industry.
  • RHK's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.4%
PM (TTM) 2.02%
GM 66.87%
OM growth 3Y1.67%
OM growth 5Y10.96%
PM growth 3Y5.16%
PM growth 5Y80.11%
GM growth 3Y-1.1%
GM growth 5Y-0.61%
RHK.DE Yearly Profit, Operating, Gross MarginsRHK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RHK.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RHK is destroying value.
  • Compared to 1 year ago, RHK has about the same amount of shares outstanding.
  • RHK has about the same amout of shares outstanding than it did 5 years ago.
  • The debt/assets ratio for RHK has been reduced compared to a year ago.
RHK.DE Yearly Shares OutstandingRHK.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
RHK.DE Yearly Total Debt VS Total AssetsRHK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 3.26 indicates that RHK is not in any danger for bankruptcy at the moment.
  • RHK has a better Altman-Z score (3.26) than 88.89% of its industry peers.
  • A Debt/Equity ratio of 0.09 indicates that RHK is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.09, RHK belongs to the top of the industry, outperforming 96.30% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 3.26
ROIC/WACC0.33
WACC6.74%
RHK.DE Yearly LT Debt VS Equity VS FCFRHK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • RHK has a Current Ratio of 2.60. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
  • RHK's Current ratio of 2.60 is amongst the best of the industry. RHK outperforms 92.59% of its industry peers.
  • A Quick Ratio of 2.49 indicates that RHK has no problem at all paying its short term obligations.
  • RHK's Quick ratio of 2.49 is amongst the best of the industry. RHK outperforms 92.59% of its industry peers.
Industry RankSector Rank
Current Ratio 2.6
Quick Ratio 2.49
RHK.DE Yearly Current Assets VS Current LiabilitesRHK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. RHK.DE Growth Analysis

3.1 Past

  • The earnings per share for RHK have decreased strongly by -21.07% in the last year.
  • The Earnings Per Share has been growing by 88.40% on average over the past years. This is a very strong growth
  • The Revenue has been growing slightly by 6.84% in the past year.
  • RHK shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.62% yearly.
EPS 1Y (TTM)-21.07%
EPS 3Y11.09%
EPS 5Y88.4%
EPS Q2Q%-25.1%
Revenue 1Y (TTM)6.84%
Revenue growth 3Y5.64%
Revenue growth 5Y4.62%
Sales Q2Q%4.24%

3.2 Future

  • Based on estimates for the next years, RHK will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.81% on average per year.
  • The Revenue is expected to grow by 5.46% on average over the next years.
EPS Next Y17.01%
EPS Next 2Y14.65%
EPS Next 3Y13.68%
EPS Next 5Y13.81%
Revenue Next Year3.87%
Revenue Next 2Y6.19%
Revenue Next 3Y5.92%
Revenue Next 5Y5.46%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
RHK.DE Yearly Revenue VS EstimatesRHK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B
RHK.DE Yearly EPS VS EstimatesRHK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

3

4. RHK.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 24.12, the valuation of RHK can be described as rather expensive.
  • Based on the Price/Earnings ratio, RHK is valued a bit more expensive than 62.96% of the companies in the same industry.
  • RHK is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.35, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 16.09, which indicates a correct valuation of RHK.
  • RHK's Price/Forward Earnings is on the same level as the industry average.
  • RHK is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.23, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 24.12
Fwd PE 16.09
RHK.DE Price Earnings VS Forward Price EarningsRHK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RHK indicates a rather cheap valuation: RHK is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.36
RHK.DE Per share dataRHK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20 25

4.3 Compensation for Growth

  • RHK's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as RHK's earnings are expected to grow with 13.68% in the coming years.
PEG (NY)1.42
PEG (5Y)0.27
EPS Next 2Y14.65%
EPS Next 3Y13.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. RHK.DE Dividend Analysis

5.1 Amount

  • RHK has a Yearly Dividend Yield of 1.63%.
  • RHK's Dividend Yield is comparable with the industry average which is at 1.64.
  • RHK's Dividend Yield is comparable with the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 1.63%

5.2 History

  • The dividend of RHK decreases each year by -19.15%.
Dividend Growth(5Y)-19.15%
Div Incr Years1
Div Non Decr Years1
RHK.DE Yearly Dividends per shareRHK.DE Yearly Dividends per shareYearly Dividends per share 2019 2023 2025 2026 0.05 0.1 0.15 0.2 0.25

5.3 Sustainability

  • 19.44% of the earnings are spent on dividend by RHK. This is a low number and sustainable payout ratio.
DP19.44%
EPS Next 2Y14.65%
EPS Next 3Y13.68%
RHK.DE Yearly Income VS Free CF VS DividendRHK.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M
RHK.DE Dividend Payout.RHK.DE Dividend Payout, showing the Payout Ratio.RHK.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

RHK.DE Fundamentals: All Metrics, Ratios and Statistics

RHOEN-KLINIKUM AG

FRA:RHK (4/27/2026, 4:02:46 PM)

12.3

-0.1 (-0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-26
Earnings (Next)05-07
Inst Owners0.53%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap823.61M
Revenue(TTM)1.70B
Net Income(TTM)34.47M
Analysts74.29
Price Target14.45 (17.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.63%
Yearly Dividend0.1
Dividend Growth(5Y)-19.15%
DP19.44%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.11%
Valuation
Industry RankSector Rank
PE 24.12
Fwd PE 16.09
P/S 0.48
P/FCF N/A
P/OCF 14.4
P/B 0.62
P/tB 0.71
EV/EBITDA 0.36
EPS(TTM)0.51
EY4.15%
EPS(NY)0.76
Fwd EY6.21%
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)0.85
OCFY6.95%
SpS25.46
BVpS19.72
TBVpS17.21
PEG (NY)1.42
PEG (5Y)0.27
Graham Number15.0438 (22.31%)
Profitability
Industry RankSector Rank
ROA 1.89%
ROE 2.61%
ROCE 2.77%
ROIC 2.24%
ROICexc 3.53%
ROICexgc 4.31%
OM 2.4%
PM (TTM) 2.02%
GM 66.87%
FCFM N/A
ROA(3y)2.14%
ROA(5y)1.92%
ROE(3y)3.02%
ROE(5y)2.69%
ROIC(3y)2.41%
ROIC(5y)2.18%
ROICexc(3y)3.18%
ROICexc(5y)2.84%
ROICexgc(3y)3.77%
ROICexgc(5y)3.38%
ROCE(3y)2.99%
ROCE(5y)2.71%
ROICexgc growth 3Y5.1%
ROICexgc growth 5Y14.06%
ROICexc growth 3Y5.79%
ROICexc growth 5Y14.64%
OM growth 3Y1.67%
OM growth 5Y10.96%
PM growth 3Y5.16%
PM growth 5Y80.11%
GM growth 3Y-1.1%
GM growth 5Y-0.61%
F-Score6
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA 1.12
Cap/Depr 152.7%
Cap/Sales 5.81%
Interest Coverage 13.22
Cash Conversion 54.02%
Profit Quality N/A
Current Ratio 2.6
Quick Ratio 2.49
Altman-Z 3.26
F-Score6
WACC6.74%
ROIC/WACC0.33
Cap/Depr(3y)120.3%
Cap/Depr(5y)111.07%
Cap/Sales(3y)4.84%
Cap/Sales(5y)4.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.07%
EPS 3Y11.09%
EPS 5Y88.4%
EPS Q2Q%-25.1%
EPS Next Y17.01%
EPS Next 2Y14.65%
EPS Next 3Y13.68%
EPS Next 5Y13.81%
Revenue 1Y (TTM)6.84%
Revenue growth 3Y5.64%
Revenue growth 5Y4.62%
Sales Q2Q%4.24%
Revenue Next Year3.87%
Revenue Next 2Y6.19%
Revenue Next 3Y5.92%
Revenue Next 5Y5.46%
EBIT growth 1Y-15.46%
EBIT growth 3Y7.4%
EBIT growth 5Y16.08%
EBIT Next Year147.39%
EBIT Next 3Y44.65%
EBIT Next 5Y28.92%
FCF growth 1Y-173.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.17%
OCF growth 3Y-1.74%
OCF growth 5Y-12.78%

RHOEN-KLINIKUM AG / RHK.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?

ChartMill assigns a fundamental rating of 5 / 10 to RHK.DE.


What is the valuation status of RHOEN-KLINIKUM AG (RHK.DE) stock?

ChartMill assigns a valuation rating of 3 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.


How profitable is RHOEN-KLINIKUM AG (RHK.DE) stock?

RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 5 / 10.


How financially healthy is RHOEN-KLINIKUM AG?

The financial health rating of RHOEN-KLINIKUM AG (RHK.DE) is 7 / 10.


What is the earnings growth outlook for RHOEN-KLINIKUM AG?

The Earnings per Share (EPS) of RHOEN-KLINIKUM AG (RHK.DE) is expected to grow by 17.01% in the next year.